PASG
Passage BIO, Inc.
Key Financials
Operating Income
$-49296000
↑ 30.0%
Net Income
$-45522000
↑ 29.7%
Total Assets
$62.3M
↓ 39.2%
Total Liabilities
$43.5M
↑ 5.8%
EPS (Diluted)
$-14.35
↓ 1241.1%
Shareholders' Equity
$18.8M
↓ 69.4%
Cash & Equivalents
$46.3M
↑ 23.2%
Operating Cash Flow
$-31509000.00
↑ 34.3%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| SCHEDULE 13G/A | 8/14/2026 | View on SEC |
| 10-Q | 8/10/2026 | View on SEC |
| 425 | 7/22/2026 | View on SEC |
| S-4 | 7/21/2026 | View on SEC |
| SCHEDULE 13D | 7/2/2026 | View on SEC |
| 4 | 6/29/2026 | View on SEC |
| SCHEDULE 13G | 6/25/2026 | View on SEC |
| 425 | 6/24/2026 | View on SEC |
| 425 | 6/24/2026 | View on SEC |
| 8-K | 6/24/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | PASG |
| Company Name | Passage BIO, Inc. |
| CIK | 1787297 |
| Sector | Biological Products, (No Diagnostic Substances) |
| Industry | Non-accelerated filer Smaller reporting company |
| Exchange | Nasdaq |
| SIC Code | 2836 |
| SIC Description | Biological Products, (No Diagnostic Substances) |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | DE |
| Phone | 2678660312 |